## Prevention of rotavirus gastroenteritis among infants a the Advisory Committee on Immunization Practices (A

MMWR Recommendations and Reports 58, 1-25

**Citation Report** 

#	Article	IF	CITATIONS
1	The Burden of Rotavirus Hospitalizations Among Medicaid and Non-Medicaid Children Younger Than 5 Years Old. American Journal of Public Health, 2009, 99, S398-S404.	1.5	11
2	An Update on Childhood and Adolescent Vaccines. Mayo Clinic Proceedings, 2009, 84, 457-460.	1.4	1
3	Public health impact and cost effectiveness of mass vaccination with live attenuated human rotavirus vaccine (RIX4414) in India: model based analysis. BMJ: British Medical Journal, 2009, 339, b3653-b3653.	2.4	52
4	HPV Vaccination's Second Act: Promotion, Competition, and Compulsion. American Journal of Public Health, 2010, 100, 1841-1844.	1.5	23

Rotavirus genotypes in children in the Basque Country (northern Spain) over a 13-year period (July) Tj ETQq0 0 0 rg $_{1.3}^{BT}$  /Overlock 10 Tf 50

6	Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5). BMC Pediatrics, 2010, 10, 42.	0.7	10
7	Hospitalisation for rotavirus gastroenteritis in the paediatric population in the Veneto Region, Italy. BMC Public Health, 2010, 10, 636.	1.2	10
8	Rotavirus Infections and Vaccines. Paediatric Drugs, 2010, 12, 235-256.	1.3	58
9	Vaccine-Acquired Rotavirus in Infants with Severe Combined Immunodeficiency. New England Journal of Medicine, 2010, 362, 314-319.	13.9	191
10	Pentavalent Rotavirus Vaccine (RotaTeq®). Drugs, 2010, 70, 1165-1188.	4.9	33
11	Effectiveness of rotavirus vaccine in preventing hospitalization due to rotavirus gastroenteritis in young children in Connecticut, USA. Vaccine, 2010, 28, 7501-7506.	1.7	42
12	Spotlight on Pentavalent Rotavirus Vaccine (RotaTeq®) in the Prevention of Rotavirus Gastroenteritis in Europeâ€. BioDrugs, 2010, 24, 411-414.	2.2	1
13	Rotavirus Vaccine RIX4414 (Rotarixâ,,¢). Pharmacoeconomics, 2011, 29, 439-454.	1.7	17
14	Rotavirus Vaccine RIX4414 (Rotarixâ"¢). Pharmacoeconomics, 2011, 29, 989-1009.	1.7	14
15	Leveraging State Immunization Information Systems to Measure the Effectiveness of Rotavirus Vaccine. Pediatrics, 2011, 128, e1474-e1481.	1.0	39
16	Detection of fecal shedding of rotavirus vaccine in infants following their first dose of pentavalent rotavirus vaccine. Vaccine, 2011, 29, 4151-4155.	1.7	60
17	Heterogeneity of Rotavirus Testing and Admitting Practices for Gastroenteritis among 12 Tertiary Care Pediatric Hospitals: Implications for Surveillance. Canadian Journal of Infectious Diseases and Medical Microbiology, 2011, 22, 15-18.	0.7	10
18	Immunology of gut mucosal vaccines. Immunological Reviews, 2011, 239, 125-148.	2.8	207

#	Article	IF	CITATIONS
19	Hospitalizations due to rotavirus gastroenteritis in Catalonia, Spain, 2003-2008. BMC Research Notes, 2011, 4, 429.	0.6	17
20	Rotarix in Japan: Expectations and Concerns. Biologics in Therapy, 2011, 1, 4.	1.8	0
21	Hospital Epidemiology and Infection Control in Acute-Care Settings. Clinical Microbiology Reviews, 2011, 24, 141-173.	5.7	458
22	<i>Tylosema esculentum</i> (Marama) Tuber and Bean Extracts Are Strong Antiviral Agents against Rotavirus Infection. Evidence-based Complementary and Alternative Medicine, 2011, 2011, 1-11.	0.5	23
23	First Reports of Human Rotavirus G8P[4] Gastroenteritis in the United States. Journal of Clinical Microbiology, 2012, 50, 1118-1121.	1.8	20
24	Gastrointestinal Microbiota and Some Children Diseases: A Review. Gastroenterology Research and Practice, 2012, 2012, 1-12.	0.7	40
25	Diversity and Relationships of Cocirculating Modern Human Rotaviruses Revealed Using Large-Scale Comparative Genomics. Journal of Virology, 2012, 86, 9148-9162.	1.5	45
26	The potential economic value of a human norovirus vaccine for the United States. Vaccine, 2012, 30, 7097-7104.	1.7	86
27	Effectiveness of rotavirus vaccination in prevention of hospital admissions for rotavirus gastroenteritis among young children in Belgium: case-control study. BMJ, The, 2012, 345, e4752-e4752.	3.0	124
28	Potential impact of accelerating the primary dose of rotavirus vaccine in infants. Vaccine, 2012, 30, 2738-2741.	1.7	2
29	Pharmacoeconomic Spotlight on Rotavirus Vaccine RIX4414 (Rotarixâ,,¢) in Developed Countries. Drugs in R and D, 2012, 12, 239-244.	1.1	3
30	Pharmacoeconomic Spotlight on Rotavirus Vaccine RIX4414 (Rotarixâ,,¢) in the Prevention of Rotavirus Gastroenteritis in Developing Countries. Paediatric Drugs, 2012, 14, 429-433.	1.3	0
31	Consensus recommendations on immunization and IAP immunization timetable 2012. Indian Pediatrics, 2012, 49, 549-564.	0.2	40
32	A Cost Effectiveness and Capacity Analysis for the Introduction of Universal Rotavirus Vaccination in Kenya: Comparison between Rotarix and RotaTeq Vaccines. PLoS ONE, 2012, 7, e47511.	1.1	31
33	Epidemiology and potential preventative measures for viral infections in children with malignancy and those undergoing hematopoietic cell transplantation. Pediatric Blood and Cancer, 2012, 59, 11-15.	0.8	11
34	The impact of Rotavirus mass vaccination on hospitalization rates, nosocomial Rotavirus gastroenteritis and secondary blood stream infections. BMC Infectious Diseases, 2013, 13, 112.	1.3	64
35	Effectiveness of Pentavalent and Monovalent Rotavirus Vaccines in Concurrent Use Among US Children <5 Years of Age, 2009–2011. Clinical Infectious Diseases, 2013, 57, 13-20.	2.9	146
36	Rotavirus-associated hospitalization and emergency department costs and rotavirus vaccine program impact. Vaccine, 2013, 31, 4164-4171.	1.7	26

		15	<b>C</b>
#	ARTICLE Noroviruses: The Most Common Pediatric Viral Enteric Pathogen at a Large University Hospital After	lF	CITATIONS
37	Introduction of Rotavirus Vaccination. Journal of the Pediatric Infectious Diseases Society, 2013, 2, 57-60.	0.6	145
38	Rotavirus vaccine RIX4414 (Rotarix®): a guide to its use in preventing rotavirus gastroenteritis in the EU. Drugs and Therapy Perspectives, 2013, 29, 130-134.	0.3	0
40	Diagnostic performance of rectal swab versus bulk stool specimens for the detection of rotavirus and norovirus: Implications for outbreak investigations. Journal of Clinical Virology, 2013, 58, 678-682.	1.6	22
41	Treatment and Prevention of Rotavirus Infection in Children. Current Infectious Disease Reports, 2013, 15, 242-250.	1.3	15
42	Targeted rotavirus vaccination of high-risk infants; a low cost and highly cost-effective alternative to universal vaccination. BMC Medicine, 2013, 11, 112.	2.3	38
43	Adoption of Rotavirus Vaccine by U.S. Physicians. American Journal of Preventive Medicine, 2013, 44, 56-62.	1.6	16
44	A critical literature review of health economic evaluations of rotavirus vaccination. Human Vaccines and Immunotherapeutics, 2013, 9, 1272-1288.	1.4	33
45	Detection of Novel Rotavirus Strain by Vaccine Postlicensure Surveillance. Emerging Infectious Diseases, 2013, 19, 1321-1323.	2.0	14
46	Editorial Commentary: Challenges to Estimating Norovirus Disease Burden. Journal of the Pediatric Infectious Diseases Society, 2013, 2, 61-62.	0.6	14
47	Effectiveness of Monovalent and Pentavalent Rotavirus Vaccine. Pediatrics, 2013, 132, e25-e33.	1.0	105
48	Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Pediatric Infectious Disease Journal, 2013, 32, i.	1.1	46
49	ÂÂAdherence to rotavirus vaccination quality measures in a commercially insured population. Human Vaccines and Immunotherapeutics, 2013, 9, 389-397.	1.4	6
50	Potential Intussusception Risk Versus Benefits of Rotavirus Vaccination in the United States. Pediatric Infectious Disease Journal, 2013, 32, 1-7.	1.1	67
51	Patterns of Rotavirus Vaccine Uptake and Use in Privately-Insured US Infants, 2006–2010. PLoS ONE, 2013, 8, e73825.	1.1	33
52	Frequency of Rotavirus and Adenovirus Gastroenteritis Among Children in Shiraz, Iran. Iranian Red Crescent Medical Journal, 2013, 15, 729-733.	0.5	32
53	Genetic Diversity of Circulating Rotavirus Strains in Tanzania Prior to the Introduction of Vaccination. PLoS ONE, 2014, 9, e97562.	1.1	36
54	Analysis by rotavirus gene 6 reverse transcriptase-polymerase chain reaction assay of rotavirus-positive gastroenteritis cases observed during the vaccination phase of the Rotavirus Efficacy and Safety Trial (REST). Human Vaccines and Immunotherapeutics, 2014, 10, 2267-2275.	1.4	6
55	Diarrhoea-related hospitalizations in children before and after implementation of monovalent rotavirus vaccination in Mexico. Bulletin of the World Health Organization, 2014, 92, 117-125.	1.5	21

#	Article	IF	CITATIONS
56	Comparative genomic analysis of genogroup 1 (Wa-like) rotaviruses circulating in the USA, 2006–2009. Infection, Genetics and Evolution, 2014, 28, 513-523.	1.0	10
57	Public health impact of accelerated immunization against rotavirus infection among children aged less than 6 months in the United States. Human Vaccines and Immunotherapeutics, 2014, 10, 2032-2038.	1.4	1
58	Novel porcine-like human G26P[19] rotavirus identified in hospitalized paediatric diarrhoea patients in Ho Chi Minh City, Vietnam. Journal of General Virology, 2014, 95, 2727-2733.	1.3	19
59	The Safety and Immunogenicity of Rotavirus Vaccination in Infants With Intestinal Failure. Journal of the Pediatric Infectious Diseases Society, 2014, 3, 57-65.	0.6	15
60	Burden of acute gastroenteritis, norovirus and rotavirus in a managed care population. Human Vaccines and Immunotherapeutics, 2014, 10, 1544-1556.	1.4	16
61	Pentavalent Rotavirus Vaccine in Infants With Surgical Gastrointestinal Disease. Journal of Pediatric Gastroenterology and Nutrition, 2014, 59, 44-48.	0.9	11
62	Clinical and cost burden of rotavirus infection before and after introduction of rotavirus vaccines among commercially and Medicaid insured children in the United States. Human Vaccines and Immunotherapeutics, 2014, 10, 2255-2266.	1.4	15
63	Immunization in Practice - Clearing the Cobwebs: Correspondence. Indian Journal of Pediatrics, 2014, 81, 422-422.	0.3	0
64	Molecular Epidemiology of Contemporary G2P[4] Human Rotaviruses Cocirculating in a Single U.S. Community: Footprints of a Globally Transitioning Genotype. Journal of Virology, 2014, 88, 3789-3801.	1.5	52
65	Direct, Indirect, Total, and Overall Effectiveness of the Rotavirus Vaccines for the Prevention of Gastroenteritis Hospitalizations in Privately Insured US Children, 2007-2010. American Journal of Epidemiology, 2014, 179, 895-909.	1.6	37
66	The Complexity of the Resurgence of Childhood Vaccine-Preventable Diseases in the United States. Current Pediatrics Reports, 2014, 2, 195-203.	1.7	4
67	Review of global rotavirus strain prevalence data from six years post vaccine licensure surveillance: Is there evidence of strain selection from vaccine pressure?. Infection, Genetics and Evolution, 2014, 28, 446-461.	1.0	194
68	Rotavirus Vaccines and Health Care Utilization for Diarrhea in the United States (2007–2011). Pediatrics, 2014, 134, 15-23.	1.0	120
69	Cost-effectiveness analysis of rotavirus vaccination among Libyan children using a simple economic model. Libyan Journal of Medicine, 2014, 9, 26236.	0.8	9
70	Gastroenteritis attributable to rotavirus in hospitalized Saudi Arabian children in the period 2007–2008. Clinical Epidemiology, 2015, 7, 129.	1.5	17
71	G2P[4]-RotaTeq Reassortant Rotavirus in Vaccinated Child, United States. Emerging Infectious Diseases, 2015, 21, 2103-2104.	2.0	4
72	Assessing bias in administrative database studies of RotaTeq vaccine completion due to exclusion of subjects with incomplete follow-up. Emerging Themes in Epidemiology, 2015, 12, 5.	1.2	6
73	Lessons Learned From Making and Implementing Vaccine Recommendations in the U.S American Journal of Preventive Medicine, 2015, 49, S406-S411.	1.6	10

#	Article	IF	CITATIONS
74	The first case of Kawasaki disease in a 20-month old baby following immunization with rotavirus vaccine and hepatitis A vaccine in China: A case report. Human Vaccines and Immunotherapeutics, 2015, 11, 2740-2743.	1.4	19
75	Effectiveness of rotavirus vaccines, licensed but not funded, against rotavirus hospitalizations in the Valencia Region, Spain. BMC Infectious Diseases, 2015, 15, 92.	1.3	27
76	Anticipating rotavirus vaccines – a pre-vaccine assessment of incidence and economic burden of rotavirus hospitalizations among children < 5 year of age in Libya, 2012-13. BMC Public Health, 2015, 1 26.	5,1.2	13
77	Long-term Consistency in Rotavirus Vaccine Protection: RV5 and RV1 Vaccine Effectiveness in US Children, 2012–2013. Clinical Infectious Diseases, 2015, 61, 1792-1799.	2.9	78
78	Association between mixed rotavirus vaccination types of infants and rotavirus acute gastroenteritis. Vaccine, 2015, 33, 5670-5677.	1.7	7
79	Catching-up with pentavalent vaccine: Exploring reasons behind lower rotavirus vaccine coverage in El Salvador. Vaccine, 2015, 33, 6865-6870.	1.7	13
80	Group A rotavirus gastroenteritis: post-vaccine era, genotypes and zoonotic transmission. Einstein (Sao Paulo, Brazil), 2016, 14, 278-287.	0.3	43
81	Rotavirus Genotypes and Vaccine Effectiveness from a Sentinel, Hospital-Based, Surveillance Study for Three Consecutive Rotavirus Seasons in Lebanon. PLoS ONE, 2016, 11, e0161345.	1.1	23
82	Decline in Emergency Department Visits for Acute Gastroenteritis Among Children in 10 US States After Implementation of Rotavirus Vaccination, 2003 to 2013. Pediatric Infectious Disease Journal, 2016, 35, 782-786.	1.1	17
83	Post-rotavirus vaccine intussusception in identical twins: A case report. Human Vaccines and Immunotherapeutics, 2016, 12, 2419-2421.	1.4	4
84	Potential safety issues and other factors that may affect the introduction and uptake of rotavirus vaccines. Clinical Microbiology and Infection, 2016, 22, S128-S135.	2.8	19
85	Rotavirus vaccination and intussusception – Science, surveillance, and safety: A review of evidence and recommendations for future research priorities in low and middle income countries. Human Vaccines and Immunotherapeutics, 2016, 12, 2580-2589.	1.4	47
86	Rotavirus Strain Trends During the Postlicensure Vaccine Era: United States, 2008–2013. Journal of Infectious Diseases, 2016, 214, 732-738.	1.9	56
87	The Immunologic Complexity of Growing Up with Malaria—Is Scientific Understanding Coming of Age?. Vaccine Journal, 2016, 23, 80-83.	3.2	5
88	Rotavirus vaccination in a Medicaid infant population from four US states: compliance, vaccination completion rate, and predictors of compliance. Human Vaccines and Immunotherapeutics, 2016, 12, 1235-1243.	1.4	7
89	Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules. Pediatrics, 2016, 137, e20152603.	1.0	28
90	Cost-Effectiveness/Cost-Benefit Analysis of Newborn Screening for Severe Combined Immune Deficiency in Washington State. Journal of Pediatrics, 2016, 172, 127-135.	0.9	40
91	Sustained Effectiveness of Monovalent and Pentavalent RotavirusÂVaccines in Children. Journal of Pediatrics, 2016, 172, 116-120.e1.	0.9	16

#	Article	IF	CITATIONS
92	Rotavirus immunization: Global coverage and local barriers for implementation. Vaccine, 2017, 35, 1637-1644.	1.7	31
93	Shedding of porcine circovirus type 1 DNA and rotavirus RNA by infants vaccinated with Rotarix®. Human Vaccines and Immunotherapeutics, 2017, 13, 928-935.	1.4	12
94	Rotavirus vaccination rate disparities seen among infants with acute gastroenteritis in Georgia. Ethnicity and Health, 2017, 22, 585-595.	1.5	2
95	Long-term impact of self-financed rotavirus vaccines on rotavirus-associated hospitalizations and costs in the Valencia Region, Spain. BMC Infectious Diseases, 2017, 17, 267.	1.3	18
96	Investigation of Rotavirus with Various Methods in Children with Acute Gastroenteritis and Determination of Its Molecular Epidemiology in Kayseri Province, Turkey. Journal of Clinical Laboratory Analysis, 2017, 31, e22030.	0.9	5
97	2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea. Clinical Infectious Diseases, 2017, 65, e45-e80.	2.9	339
98	Relationship between Pentavalent Rotavirus Vaccine and Intussusception: A Retrospective Study at a Single Center in Korea. Yonsei Medical Journal, 2017, 58, 631.	0.9	5
99	Association Between Estimated Cumulative Vaccine Antigen Exposure Through the First 23 Months of Life and Non–Vaccine-Targeted Infections From 24 Through 47 Months of Age. JAMA - Journal of the American Medical Association, 2018, 319, 906.	3.8	43
100	Modeling environmentally mediated rotavirus transmission: The role of temperature and hydrologic factors. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E2782-E2790.	3.3	38
101	Effect of Rotavirus Vaccination on Acute Diarrheal Hospitalizations Among Low and Very Low Birth Weight US Infants, 2001–2015. Pediatric Infectious Disease Journal, 2018, 37, 817-822.	1.1	7
102	Lack of impact of rotavirus vaccines on seizure-related hospitalizations in children under 5Âyears old in Spain. Human Vaccines and Immunotherapeutics, 2018, 14, 1534-1538.	1.4	12
103	The global problem of childhood diarrhoeal diseases: emerging strategies in prevention and management. Therapeutic Advances in Infectious Disease, 2018, 5, 29-43.	1.1	132
104	Trends in Rate of Seizure-Associated Hospitalizations Among Children <5 Years Old Before and After Rotavirus Vaccine Introduction in the United Sates, 2000–2013. Journal of Infectious Diseases, 2018, 217, 581-588.	1.9	17
105	Pentavalent rotavirus vaccine (RotaTeq®) in the prevention of rotavirus gastroenteritis: a profile of its use in the EU. Drugs and Therapy Perspectives, 2018, 34, 143-149.	0.3	2
106	Rotavirus Vaccines and Health Care Utilization for Diarrhea in US Children, 2001 to 2015. Pediatric Infectious Disease Journal, 2018, 37, 943-948.	1.1	12
107	Monitoring Shedding of Five Genotypes of RotaTeq Vaccine Viruses by Genotype-Specific Real-Time Reverse Transcription-PCR Assays. Journal of Clinical Microbiology, 2018, 56, .	1.8	7
108	Antibody secreting B cells and plasma antibody response to rotavirus vaccination in infants from Kolkata India. Heliyon, 2018, 4, e00519.	1.4	7
109	Open-Label Pilot Study to Compare the Safety and Immunogenicity of Pentavalent Rotavirus Vaccine (RV5) Administered on an Early Alternative Dosing Schedule with Those of RV5 Administered on the Recommended Standard Schedule. Journal of the Pediatric Infectious Diseases Society, 2018, 7, 82-85.	0.6	7

#	Article	IF	CITATIONS
110	Rotavirus Vaccination Is Associated With Reduced Seizure Hospitalization Risk Among Commercially Insured US Children. Clinical Infectious Diseases, 2018, 67, 1614-1616.	2.9	13
111	A decade of experience with rotavirus vaccination in the United States – vaccine uptake, effectiveness, and impact. Expert Review of Vaccines, 2018, 17, 593-606.	2.0	72
112	Rotavirus vaccination and shortâ€ŧerm risk of adverse events in <scp>US</scp> infants. Paediatric and Perinatal Epidemiology, 2018, 32, 448-457.	0.8	15
113	Reports of lower respiratory tract infection following dose 1 of RotaTeq and Rotarix vaccines to the Vaccine Adverse Event Reporting System (VAERS), 2008–2016. Human Vaccines and Immunotherapeutics, 2018, 14, 1-5.	1.4	5
114	Understanding FDA-Approved Labeling and CDC Recommendations for Use of Vaccines. Pediatrics, 2018, 142, .	1.0	9
115	Longer-term Direct and Indirect Effects of Infant Rotavirus Vaccination Across All Ages in the United States in 2000–2013: Analysis of a Large Hospital Discharge Data Set. Clinical Infectious Diseases, 2019, 68, 976-983.	2.9	28
116	Rotavirus Burden, Genetic Diversity and Impact of Vaccine in Children under Five in Tanzania. Pathogens, 2019, 8, 210.	1.2	6
117	Geospatial Variation in Rotavirus Vaccination in Infants, United States, 2010–2017. Emerging Infectious Diseases, 2019, 25, 1993-1995.	2.0	4
118	Association of Rotavirus Vaccination With Inpatient and Emergency Department Visits Among Children Seeking Care for Acute Gastroenteritis, 2010-2016. JAMA Network Open, 2019, 2, e1912242.	2.8	18
119	Decline in Pneumococcal Disease Attenuated in Older Adults and Those With Comorbidities Following Universal Childhood PCV13 Immunization. Clinical Infectious Diseases, 2019, 68, 1831-1838.	2.9	28
120	Vaccinations in pediatric kidney transplant recipients. Pediatric Nephrology, 2019, 34, 579-591.	0.9	15
121	Rotavirus Vaccination Coverage During a Rotavirus Outbreak Resulting in a Fatality at a Subacute Care Facility. Journal of the Pediatric Infectious Diseases Society, 2020, 9, 287-292.	0.6	6
122	Geospatial distribution of severe paediatric intussusception in KwaZulu-Natal province, South Africa. Pan African Medical Journal, 2020, 36, 320.	0.3	2
123	Unusual mono-reassortant of a Wa-like G1P[8] species A rotavirus containing a DS-1-like (genotype 2) NSP4 gene. Virus Genes, 2020, 56, 638-641.	0.7	5
124	Does Rotavirus Vaccination Affect Longer-Term Intussusception Risk in US Infants?. Journal of the Pediatric Infectious Diseases Society, 2020, 9, 257-260.	0.6	11
125	Overview of the Development, Impacts, and Challenges of Live-Attenuated Oral Rotavirus Vaccines. Vaccines, 2020, 8, 341.	2.1	24
126	Surveillance data confirm multiyear predictions of rotavirus dynamics in New York City. Science Advances, 2020, 6, eaax0586.	4.7	7
127	Disease burden and seasonal impact of improving rotavirus vaccine coverage in the United States: AÂmodeling study. PLoS ONE, 2020, 15, e0228942.	1.1	5

#	Article	IF	CITATIONS
128	Rotavirus Vaccine Is Effective Against Rotavirus Gastroenteritis Resulting in Outpatient Care: Results From the Medically Attended Acute Gastroenteritis (MAAGE) Study. Clinical Infectious Diseases, 2021, 72, 2000-2005.	2.9	3
129	Rotavirus vaccination in the US: a systematic review of vaccination coverage and completion. Human Vaccines and Immunotherapeutics, 2021, 17, 872-879.	1.4	5
130	Comparative genomic analysis of genogroup 1 and genogroup 2 rotaviruses circulating in seven US cities, 2014–2016. Virus Evolution, 2021, 7, veab023.	2.2	15
131	Infection status and circulating strains of rotaviruses in Chinese children younger than 5-years old from 2011 to 2018: systematic review and meta-analysis. Human Vaccines and Immunotherapeutics, 2021, 17, 1811-1817.	1.4	12
132	Estimating the Effectiveness of Rotavirus Vaccine Schedules. Epidemiology, 2021, 32, 598-606.	1.2	3
133	Why Aren't We Achieving High Vaccination Rates for Rotavirus Vaccine in the United States?. Academic Pediatrics, 2021, , .	1.0	2
134	Prevalence, Pattern and Genetic Diversity of Rotaviruses among Children under 5 Years of Age with Acute Gastroenteritis in South Africa: A Systematic Review and Meta-Analysis. Viruses, 2021, 13, 1905.	1.5	9
135	Observations on the epidemiology of rotavirus infection among hospitalized children younger than 5†years in 2 Ukrainian hospitals, 2007–2015. Vaccine, 2018, 36, 7798-7804.	1.7	7
136	Recommendations for the use of rotavirus vaccines in infants. Paediatrics and Child Health, 2010, 15, 519-523.	0.3	9
137	A Case of Henoch-Schonlein Purpura Associated with Rotavirus Infection in an Elderly Asian Male and Review of the Literature. American Journal of Case Reports, 2017, 18, 136-142.	0.3	8
138	Rotavirus Vaccines: a story of success with challenges ahead. F1000Research, 2017, 6, 1517.	0.8	15
139	Public Health Impact of Complete and Incomplete Rotavirus Vaccination among Commercially and Medicaid Insured Children in the United States. PLoS ONE, 2016, 11, e0145977.	1.1	13
140	Updated Statement on the use of Rotavirus Vaccines. Canada Communicable Disease Report, 2010, 36, 1-37.	0.6	10
141	Three Rotavirus Outbreaks in the Postvaccine Era — California, 2017. Morbidity and Mortality Weekly Report, 2018, 67, 470-472.	9.0	18
142	Trends in the Laboratory Detection of Rotavirus Before and After Implementation of Routine Rotavirus Vaccination — United States, 2000–2018. Morbidity and Mortality Weekly Report, 2019, 68, 539-543.	9.0	46
143	Prevalence and genotype distribution of rotaviruses in children with gastroenteritis in Rize province. Bosnian Journal of Basic Medical Sciences, 2015, 15, 35-39.	0.6	7
144	Distribution of Rotavirus Genotypes Ccirculating in Ahvaz, Iran in 2016. Iranian Biomedical Journal, 2018, 22, 107-16.	0.4	9
145	Prevalence of rotavirus genotypes in South Korea in 1989-2009: implications for a nationwide rotavirus vaccine program. Korean Journal of Pediatrics, 2013, 56, 465.	1.9	21

#	Article	IF	CITATIONS
146	Evaluation of the Field Performance of ImmunoCard STAT!® Rapid Diagnostic Test for Rotavirus in Dadaab Refugee Camp and at the Kenya–Somalia Border. American Journal of Tropical Medicine and Hygiene, 2017, 96, 1302-1306.	0.6	7
147	Childhood Immunization Policies and the Prevention of Communicable Disease. Pediatric Annals, 2011, 40, 136-143.	0.3	0
148	Pharmacoeconomic Spotlight on Rotavirus Vaccine RIX4414 (Rotarixâ,,¢) in the Prevention of Rotavirus Gastroenteritis in Developing Countriesâ€. Paediatric Drugs, 2012, 14, 429-433.	1.3	3
149	Acute Gastroenteritis Disease Burden in Infants With Medical Risk Conditions in the Netherlands. Pediatric Infectious Disease Journal, 2021, 40, 300-305.	1.1	5
150	Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recommendations and Reports, 2009, 58, 1-166.	26.7	90
151	Rotavirus diversity and evolution in the post-vaccine world. Discovery Medicine, 2012, 13, 85-97.	0.5	89
152	Rota Viral Infection: A Significant Disease Burden to Libya. Iranian Journal of Public Health, 2014, 43, 1356-63.	0.3	4
153	Sustained decrease in laboratory detection of rotavirus after implementation of routine vaccination—United States, 2000-2014. Morbidity and Mortality Weekly Report, 2015, 64, 337-42.	9.0	64
154	Notes from the field: rotavirus vaccine administration errorsUnited States, 2006-2013. Morbidity and Mortality Weekly Report, 2014, 63, 81.	9.0	11
155	PREVALENCE AND RELATIVE RISK OF ROTAVIRUS GASTROENTERITIS IN CHILDREN UNDER FIVE YEARS IN NIGERIA: A SYSTEMATIC REVIEW AND META-ANALYSIS. Pathogens and Global Health, 2022, , 1-12.	1.0	0
156	Rotavirus genotypes and clinical outcome of natural infection based on vaccination status in the post-vaccine era. Human Vaccines and Immunotherapeutics, 2022, 18, 1-7.	1.4	5
157	Acceptance and application of a broad population health perspective when evaluating vaccine. Vaccine, 2022, 40, 3395-3401.	1.7	4
158	Understanding Variation in Rotavirus Vaccine Effectiveness Estimates in the United States: The Role of Rotavirus Activity and Diagnostic Misclassification. Epidemiology, 2022, Publish Ahead of Print, .	1.2	1